(Q46226517)

20 December 2017

title

Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective (English)

1 reference

20 December 2017

author name string

J Teras

1

1 reference

20 December 2017

J Gardovskis

2

1 reference

20 December 2017

T Vaasna

3

1 reference

20 December 2017

U Kupcs

4

1 reference

20 December 2017

G Pupelis

5

1 reference

20 December 2017

G Dukart

6

1 reference

20 December 2017

N Dartois

7

1 reference

20 December 2017

S Jouve

8

1 reference

20 December 2017

A Cooper

9

1 reference

20 December 2017

305 Study Group

10

1 reference

20 December 2017

publication date

1 October 2008

1 reference

20 December 2017

published in

Journal of Chemotherapy

1 reference

20 December 2017

volume

20 Suppl 1

1 reference

20 December 2017

page(s)

20-27

1 reference

20 December 2017

Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Why is big Pharma getting out of antibacterial drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Staphylococcus aureus: a well-armed pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Effect of tigecycline on normal oropharyngeal and intestinal microflora

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Community-acquired methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

Tigecycline: what is it, and where should it be used?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2008.20.SUPPLEMENT-1.20

10.1179/JOC.2008.20.SUPPLEMENT-1.20

21 January 2018

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017